RNA splicing factor USP39 promotes glioma progression by inducing TAZ mRNA maturation

Kaikai Ding1,2, Jianxiong Ji1,2, Xin Zhang1,2, Bin Huang1,2, Anjing Chen1,2, Di Zhang1,2, Xingang Li1,2, Xinyu Wang1,2, Jian Wang1,2,3

Received: 23 October 2018 / Revised: 6 June 2019 / Accepted: 3 July 2019 / Published online: 22 July 2019
© The Author(s) 2019. This article is published with open access

Abstract
Increasing evidence demonstrates that ubiquitin specific protease 39 (USP39) plays an oncogenic role in various human tumors. Here, using expression analysis of the publicly available Oncomine database, clinical glioma patient samples, and glioma cells, we found that USP39 was overexpressed in human gliomas. Knockdown of USP39 in glioma cells demonstrated that the protein promoted cell growth, invasion and migration in vitro and in a tumor model in nude mice. To identify mediators of USP39 growth-promoting properties, we used luciferase reporter constructs under transcriptional control of various promoters specific to seven canonical cancer-associated pathways. Luciferase activity from a synthetic TEAD-dependent YAP/TAZ-responsive reporter, as a direct readout of the Hippo signaling pathway, was decreased by 92% in cells with USP39 knockdown, whereas the luciferase activities from the other six cancer pathways, including MAPK/ERK, MAPK/JNK, NFκB, Notch, TGFβ, and Wnt, remained unchanged. TAZ protein expression however was decreased independent of canonical Hippo signaling. Immunohistochemistry revealed a positive correlation between USP39 and TAZ proteins in orthotopic xenografts derived from modified glioma cells expressing USP39 shRNAs and primary human glioma samples (p < 0.05). Finally, loss of USP39 decreased TAZ pre-mRNA splicing efficiency in glioma cells in vitro, which led to reduced levels of TAZ protein. In summary, USP39 has oncogenic properties that increase TAZ protein levels by inducing maturation of its mRNA. USP39 therefore provides a novel therapeutic target for the treatment of human glioma.

Introduction
Malignant gliomas are the most common aggressive and fatal primary brain tumors in adults [1, 2]. Despite great advances in treatment, median survival for patients with glioblastoma (GBM), the most aggressive glioma, is 14.5–16.6 months [3]. The current standard of care is largely ineffective due to complex features, which include aggressive growth and diffuse invasion. In recent years, much of the research effort has focused on the molecular basis of the disease with the goal of translating this better understanding into viable therapies [4].

Ubiquitin specific protease 39 (USP39) is a member of a family of deubiquitinating proteins that are classified based on the sequence similarity in the Dub-domain. However, USP39 is interestingly entirely deprived of deubiquitinating activity due to the absence of conserved active-site residues (a cysteine, histidine, and aspartic acids) in the Dub-domain [5]. USP39 is also known as Sad1p in yeast and a 65 kDa SR-related protein in humans, both of which have been implicated in assembly
of the mature spliceosome complex, suggesting a role in mRNA splicing [6–8]. Previous studies have demonstrated that USP39 is involved in splicing of the transcript for Aurora B [5]. Mutation of zebrafish USP39 induces mRNA splicing defects in the retinoblastoma gene, rb1 [9]. USP39 is also reported to be a pivotal regulator of EGFR pre-mRNA splicing [10]. In addition, an oncogenic role for USP39 has been reported in many malignant tumors, such as prostate cancer [10], oral squamous cell carcinoma [11], gastric cancer [12], melanoma [13], osteosarcoma [14], breast cancer [15], hepatocellular carcinoma [16], medullary thyroid carcinoma [17], lung cancer [18], pancreatic cancer [19], colorectal cancer [20], and renal cell carcinoma [21]. However, the role of USP39 in glioma has not been well defined.

TAZ, also known as WWTR1 (WW-domain containing transcriptional regulator 1), a transcriptional coactivator with a PDZ-binding motif, and its paralog, yes-associated protein (YAP), are associated primarily with activity in the Hippo tumor suppressor pathway, which plays a prominent role in cell proliferation, cell apoptosis, tumor metastasis, and maintenance of stem cell traits in cancer [22–25]. Classic Hippo signaling is transmitted through a kinase cascade. The upstream kinases, MST1 and MST2, work together with the adaptor protein SAV1/WW45 to phosphorylate and activate LATS1 and LATS2. These activated LATS kinases together with MOB1 then phosphorylate the TAZ and YAP effector proteins [26]. Phosphorylated TAZ is mainly localized in the cytoplasm, whereas unphosphorylated TAZ enters the nucleus, where the protein functions as a transcriptional coactivator to promote tumor growth through the induction of gene transcription [27–29]. Elevated expression and activity of TAZ have been identified in various human cancers, such as melanoma, hepatocellular carcinoma, and breast, liver, and colorectal cancers [24, 30–32]. In addition, TAZ expression has been found to be increased, positively correlated with tumor grade, and involved in regulating mesenchymal differentiation in glioma [33, 34]. However, several aspects of the role of TAZ in glioma remain unknown.

In this work, we investigate the expression of USP39 in human gliomas and comprehensively study the functional role of USP39 in the development of the disease using model systems both in vitro and in vivo. We reveal that USP39 has growth-promoting properties in human gliomas, and investigation of putative oncogenic mechanisms illuminates a role in mRNA processing of TAZ, a transcriptional regulator with known oncogenic properties. USP39 may thus be a potential prognostic biomarker and therapeutic target in the treatment of glioma patients.

Results

Increased expression of USP39 is associated with increasing tumor grade in primary human gliomas

We first analyzed USP39 expression in human cancer in the publicly available database Oncomine. Results demonstrated that USP39 was upregulated in many tumor types, including brain and CNS cancer (Supplementary Fig. 1a). We then analyzed USP39 mRNA expression specifically in GBM, and found that the numbers of samples in TCGA and Sun Brain datasets are greater (>100 samples) than in other datasets. In these two datasets, USP39 was distinctly upregulated in GBM compared with nonneoplastic brain tissue samples (Supplementary Fig. 1b).

We validated these in silico results first through immunohistochemical (IHC) staining of primary human glioma samples. Staining for USP39 was increased in glioma samples (Fig. 1a), and levels in high-grade gliomas (WHO III–IV; n = 28) were increased compared with low-grade gliomas (WHO II; n = 18) and nonneoplastic human brain tissue samples (n = 6, Fig. 1b). These results indicated that USP39 protein expression was correlated with higher tumor grade. We verified that USP39 expression was associated with tumor grade, independent from other clinicopathological factors, including age, gender, tumor size, cystic change, and edema, which suggested that USP39 could be a potential diagnostic factor for glioma patients (Table 1, p < 0.05). Western blotting analysis of primary human glioma samples further supported these findings. USP39 protein levels were increased in high-grade glioma samples (WHO III–IV; n = 8) relative to low-grade glioma (WHO II; n = 4) and nonneoplastic human brain tissue samples (n = 3; Fig. 1c).

We also examined USP39 mRNA and protein levels in several cell types in culture, including P3, LN18, U87MG, U251, and A172 glioma cells, and normal human astrocytes (NHA), using qRT-PCR and western blotting. USP39 mRNA and protein expression were significantly higher in the glioma cell populations than in NHA (1.9–4.2×; Fig. 1d, e). These data all together indicated that increased expression of USP39 is associated with increasing tumor grade in gliomas and that the protein may be involved in glioma progression.

USP39 promotes proliferation, invasion, and migration of glioma cells in vitro

To examine the function of the protein in glioma development, we knocked down expression of USP39 in glioma cells in culture with short hairpin RNAs (shRNAs) in lentiviral constructs. Expression of USP39 was high in all glioma cells tested relative to NHA (Fig. 1e), so we
randomly chose U87MG, A172, and P3 glioma cells for these experiments. ShRNAs targeting two different coding regions of USP39 (sh-USP39-1 and sh-USP39-2) were designed and tested in the three glioma cell populations. Both efficiently knocked down *USP39* mRNA by about 80% and protein expression by about 60% in all three glioma cell populations (Fig. 2a, b). Cell growth was significantly reduced in cells expressing the USP39 shRNAs as assessed in three different assays, including Cell Counting Kit-8 (CCK8), colony forming, and EdU assays (Fig. 2c–f and Supplementary Fig. 2a), compared with negative controls (NC). In cell invasion and migration assays, the number of invaded and migrated cells was reduced by nearly 50% in cells expressing the USP39 shRNAs (Fig. 2g and Supplementary Fig. 2b). These findings indicated that USP39 promoted proliferation, invasion, and migration of glioma cells in vitro.

**Downregulation of USP39 reduces cell growth in vivo**

To examine the effect of USP39 on cell growth in vivo, we generated an orthotopic tumor model by implanting U87MG- and P3-NC/-sh-USP39-1 cells in the brains of nude mice. These cells were expressing luciferase, so that signal emanating from tumors could be measured over time at regular intervals. Bioluminescence signals did increase overall in mice over the 20-day time period (Fig. 3a), but USP39 knockdown led to a decreased rate in tumor growth. Total flux was used as a measure to quantify the in vivo bioluminescence imaging results. Total flux in U87MG-sh-USP39-1 tumors was markedly different at 10 days after injection of cells compared with U87MG-NC control tumors. Total flux was decreased by 45% at this time point.
By 20 days, this difference had increased with values from U87MG-sh-USP39-1 tumors being 75% less than controls (Fig. 3b). The trend was the same for P3-sh-USP39-1 cells, although the reduced tumor growth of 58% relative to controls was not evident until 15 days after implantation (Fig. 3b).

Histological examination revealed that U87MG- and P3-sh-USP39-1 orthotopic xenografts tended to be less invasive and more circumscribed than controls (Fig. 3c). Furthermore, in Kaplan–Meier analysis of survival data from tumor bearing mice, animals implanted with U87MG- and P3-sh-USP39-1 cells exhibited better overall survival (median survival: 27 days vs. 33 days, U87MG-NC and U87MG-sh-USP39-1, respectively; 26 days vs. 31 days, P3-NC and P3-sh-USP39-1, respectively; Fig. 3d). Together, these findings demonstrated that USP39 depletion led to decreased cell growth in vivo.

**USP39 regulates TAZ independently of classical Hippo signaling**

To explore the potential mechanisms underlying USP39-induced malignant behaviors in glioma, we transfected a series of luciferase reporter constructs to assay signaling activity from seven different pathways, such as Notch, Hippo, and Wnt, which are typically dysregulated in human cancers. In these constructs, luciferase is regulated by a transcriptional element specific to each pathway. We found that the luciferase activity from a synthetic TEAD-dependent YAP/TAZ-responsive reporter, as a direct
readout of Hippo activity, was decreased by 92% in U87MG-sh-USP39-1 cells, whereas the luciferase activities of the other six cancer pathways, including MAPK/ERK, MAPK/JNK, NFκB, Notch, TGFβ, and Wnt, remained unchanged (Fig. 4a).

Western blotting analysis showed that TAZ protein expression was also reduced in U87MG-, A172-, and P3-sh-USP39-1 cells relative to controls, but other key components of the Hippo pathway, including LATS1, LATS2, and YAP, remained unchanged (Fig. 4b). In view of the critical role of YAP/TAZ in activating transcription and YAP protein remained unchanged in our work, we validate the individual effect of TAZ using luciferase assays (Supplementary Fig. 3a). We hypothesized that USP39 might promote malignant behaviors through TAZ. We performed IHC on sections from the xenografts derived from the modified cell types to determine the relationship between these proteins in vivo. The IHC scores demonstrated that TAZ protein expression was decreased after knockdown of USP39

Fig. 3 Knockdown of USP39 decreases proliferation, invasion, and migration of glioma cells in vivo. a Representative images of luciferase bioluminescence at the indicated days after injection of luciferase-expressing U87MG and P3 cells into the brains of nude mice. b Graphic representation of the total flux at the indicated days for the indicated cell types. c Representative images of HE staining of orthotopic xenografts derived from the indicated cell types, U87MG- and P3-sh-USP39-1 cells and controls. Scale bars, 1000 and 200 μm. d Kaplan–Meier analysis of survival for tumor bearing mice implanted with U87MG- and P3-sh-USP39-1 cells and controls. Student’s t-test: n.s. = not significant, *p < 0.05, **p < 0.01, ***p < 0.001. Log-rank test: p < 0.01
In addition, in line with the results from Fig. 3, IHC scores for Ki67, a marker for proliferation, were correspondingly decreased (Fig. 4c, d). Finally, we performed IHC on primary human glioma samples (n = 33) and found that IHC scores for USP39 correlated with scores obtained for TAZ (p < 0.05; Fig. 4e, f). Thus, USP39 and TAZ proteins were positively correlated. All together, these results demonstrated that loss of USP39 led to decreased TAZ but not other components of the Hippo signaling pathway including LATS1/2.

**USP39 regulates TAZ protein expression through TAZ mRNA maturation**

USP39 has been reported to be involved in pre-mRNA splicing of certain genes [6–8, 35]. We therefore investigated whether

---

**Fig. 4** USP39 regulates TAZ through a LATS1/2-independent mechanism. a Graphic representation of relative luciferase activity in reporter assays to probe activation through seven cancer-associated pathways in U87MG-sh-USP39-1 cells. Luciferase reporter constructs regulated by pathway specific promoters were transfected into cells and assayed for luciferase activity. b Western blotting analysis of TAZ and other key components of the Hippo signaling pathway in U87MG-, A172-, and P3-sh-USP39-1 cells relative to controls. GAPDH was used for normalization. c Representative images of IHC staining of USP39, TAZ, and Ki67 levels in xenograft sections from U87MG-NC, U87MG-sh-USP39-1, P3-NC, and P3-sh-USP39-1 groups. Scale bars, 50 µm. d Graphic representation of IHC scores for USP39, TAZ, and Ki67 levels from indicated groups. e Representative images of IHC staining of USP39 and TAZ in primary human glioma samples (n = 33). Scale bars, 50 µm. f Correlation of USP39 and TAZ protein expression in primary human glioma samples. IHC scores are indicated in parentheses. Student’s t-test: *p < 0.05, **p < 0.01. χ²-test and Fisher’s exact test: p < 0.05.
USP39 had a role in posttranscriptional regulation of TAZ mRNA splicing. Little is currently known about mRNA splicing of TAZ transcripts and their final form. However, according to the Ensembl database, TAZ has three predicted primary transcripts, which could yield a translated product corresponding to the longest protein isoform of TAZ observed in this work. Although these predicted primary transcripts have different lengths, they share some common regions. For example, in the longest primary transcript, the region from introns 3–4 to introns 7–8 is also contained in two other primary transcripts. Because these exons (exons 4–7) are equally represented in the different transcripts, the region from exons 4 to 5 in the longest primary transcript was selected to design specific primers to distinguish TAZ spliced mRNA and TAZ unspliced mRNA (Fig. 5a). Using qRT-PCR, we detected increased levels of unspliced mRNA transcripts in U87MG-sh-USP39-1 and A172-sh-USP39-1 cells relative to controls, whereas spliced mRNA was significantly decreased (~70%; Fig. 5b, c). Besides, we performed the RNA-binding protein immunoprecipitation assay (RIP) on extracts prepared from U87MG and A172 using USP39 antibody. The results of qRT-PCR demonstrated that TAZ expression was significantly enriched in USP39 pull downs compared with IgG controls (Fig. 5d, e). These data suggested that knockdown of USP39 led to decreased TAZ protein levels at least in part by suppressing splicing of its pre-mRNA.

**Downregulation of USP39 decreases TAZ transcriptional activity**

To better clarify the regulation of TAZ by USP39, cellular localization of the TAZ protein was examined.
Knockdown of USP39 was performed in U87MG and A172 cells, and lysates were prepared from nuclear and cytoplasmic fractions. In western blotting analysis, we observed a strong decrease in the ratio of TAZ nuclear protein (normalized to Histone H3) to total protein (normalized to GAPDH) levels in modified and control (NC) cells. Immuno-fluorescence staining was consistent with these findings (Fig. 6c). Finally, transcriptional activity paralleled the loss of nuclear TAZ; mRNA levels of TAZ target genes, BIRC5, E2F1, and MYC were decreased (Fig. 6d) [22, 24, 36]. These data therefore indicated that USP39 was involved in the transcriptional activation of TAZ.

**Ectopic expression of USP39 and TAZ restores malignant properties of glioma cells with the loss of USP39 in vitro and in vivo**

To further validate the putative oncogenic role of USP39 in glioma and exclude off-target effects of the shRNAs, USP39 was overexpressed in cells with depletion of USP39. To investigate the functional role of TAZ protein in the USP39-promoted pathway in glioma, U87MG-, and P3-sh-USP39-1 cells were infected with a wild-type TAZ lentiviral expression construct. Efficiency of expression from these constructs was assessed by western blotting; USP39

---

**Fig. 6 Downregulation of USP39 decreases TAZ transcriptional activity.** a, b Western blotting analysis of total, cytoplasmic, and nuclear fractions prepared from indicated cells. Bar graph showing the ratio of TAZ nuclear protein (normalized to Histone H3) to total protein (normalized to GAPDH) levels in modified and control (NC) cells. c Representative images of immuno-fluorescence for TAZ (red) in indicated cells. Nuclei are stained with DAPI (blue). Scale bars, 100 µm. d qRT-PCR analysis for expression of TAZ target genes in U87MG- or A172-sh-USP39-1 compared with controls. GAPDH was used for normalization. Student’s t-test: n.s. = not significant, *p < 0.05, **p < 0.01, ***p < 0.001
or TAZ was increased in both U87MG- and P3-sh-USP39-1 cells (Fig. 7a).

Ectopic expression of USP39 or TAZ in U87MG- and P3-sh-USP39-1 cells restored malignant properties. Cell
proliferation reached levels observed in controls without the loss of USP39 (Fig. 7b). In addition, luciferase activity, from a Hippo pathway regulated luciferase reporter construct, was rescued in U87MG-sh-USP39-1 cells as well as transcription of genes downstream of TAZ (Fig. 7c, d). These in vitro results were further validated in vivo through orthotopic implantation of the various modified cell types. Cell growth in U87MG- and P3-sh-USP39-1 cells with USP39 or TAZ overexpression reached values similar to those obtained from control cells (Fig. 7e, f). These data overall demonstrated that TAZ was a critical downstream effector mediating the oncogenic function of USP39 in glioma.

**Discussion**

Previous studies have reported that USP39 contributes to cancer progression and predicts poor prognosis in various tumors [10–21]. For example, USP39 has been shown to be essential for KRAS-driven cancer [35]. Here, analysis of expression data from the Oncomine dataset demonstrated that *USP39* mRNA might be upregulated in GBM. We found increased protein levels of USP39 to be associated with higher tumor grade in an independent cohort of primary human gliomas. In functional experiments, we demonstrated that this increase in USP39 promotes cell proliferation, invasion, and migration in vitro and in vivo. These results are consistent with an oncogenic role for USP39 in the development of human glioma.

Based on a series of luciferase reporter assays designed to probe activity in seven cancer-associated pathways, we found that events downstream of Hippo signaling were dramatically affected by USP39 levels in glioma. Previous work from our lab supports a critical role for Hippo signaling in the development of human glioma. We found that actin like-6A (ACTL6A) promotes glioma progression by directly associating with YAP/TAZ, which prevents ubiquitination of YAP/TAZ protein. We also observed that ACTL6A mainly interacts with the C-terminal region of YAP, thus inhibiting YAP from binding to the ubiquitin ligase β-TrCP [37]. Other studies have also demonstrated a critical role for YAP/TAZ in gliomagenesis [33, 34, 38]. Therefore, we aim to identify novel mechanisms of regulation for Hippo signaling in human gliomas.

We carefully investigated the relationship between USP39 and Hippo signaling through protein analysis of key components of the pathway. Protein levels of TAZ were reduced with USP39 knockdown, but other key components in the Hippo pathway, including LATS1/2 and YAP, remained unchanged. The existence of a potential link between the protein expression of USP39 and TAZ was also supported by IHC performed on sections from xenografts derived from modified U87MG and P3 cells, as well as human primary glioma samples. Although YAP and TAZ have been reported to act synergistically to activate transcription [39], over-expression of TAZ or knockdown of TAZ alone has been found to substantially affect Hippo signaling (8 × GTIIC-Luc reporter) [40]. We verified this result in glioma, which explains why Hippo activity could be impaired even in the presence of normal protein levels of YAP. The decrease in Hippo signaling (~90%) also did not parallel the reduction in TAZ protein levels (~50%) after USP39 knockdown. TAZ is a transcriptional coactivator, which cannot directly bind to DNA, but it interacts with several oncogenic transcription factors, including TEADs, to activate transcription. A study has reported that TAZ mutants defective in interaction with TEADs failed to accumulate in the nucleus [41]. So one plausible interpretation would be that USP39 may also affect the interaction between TAZ and transcription factors, which might contribute to inhibition of Hippo signaling.

A fundamental question that remains is how USP39 drives the increase in TAZ protein. USP39 is reported to be a splicing factor and to take part in the processing of the mRNA of some genes [6–8, 35]. Although the regulation of TAZ expression has been thoroughly investigated at the transcriptional level [42], the mechanisms governing the processing of TAZ mRNA are less well understood. We provide evidence that USP39 regulates TAZ protein levels, at least in part, by controlling mRNA maturation. According to the Ensembl database, there are three primary transcripts that can be translated into full-length TAZ protein. For detection of unspliced and spliced TAZ mRNAs, we designed two primer pairs specific for a region common to all three primary transcripts. This method has been previously used to determine the splicing rate of various gene transcripts [10, 43]. Indeed, a decrease in TAZ pre-mRNA splicing efficiency was detected in cells with USP39 knockdown, implicating a role for the protein in the maturation of TAZ mRNA. Furthermore, USP39 plays a central role in...
pre-mRNA splicing of many genes, including CAS-P8AP2, CDC48, MED19, SERPINB6, TAF9B, BORA, KIF14, and ORC11 [35]. Combined with results from previous studies [5, 9, 10], it is reasonable to speculate that the effects of USP39 on the maturation of mRNA are not merely specific to TAZ mRNA.

We also demonstrated that USP39 increases TAZ protein level and thus enhances its nuclear function. However, the mechanism linking USP39 to TAZ activation is unclear. TAZ has been identified as an integral component of the β-catenin destruction complex, which effectively sequesters TAZ in the cytoplasm, and knockdown of USP39 has also been shown to lead to decreased protein expression of β-catenin [44–46]. USP39 silencing might therefore enhance the β-catenin destruction complex, and thus lead to cytoplasmic retention and reduced nuclear localization of TAZ. Further investigation is necessary to illuminate the specific mechanism.

In summary, our work indicated that upregulated expression of USP39 is a common event in human gliomas, and that it promotes malignant tumor properties in gliomas both in vitro and in vivo. Thus, USP39 appears to have oncogenic properties in the development of human gliomas. Our study further demonstrated that the oncogenic activity of USP39 is due to its ability to activate TAZ. However, this activity is independent of canonical Hippo signaling, and is instead due to its ability to enhance pre-mRNA splicing of TAZ. Finally, our work provides an important basis for the development of diagnostic and therapeutic approaches in the treatment of glioma patients using USP39.

**Materials and methods**

**Cell lines and cell culture**

Human glioma cell lines LN18, U87MG, A172, and U251 were obtained from the Culture Collection of the Chinese Academy of Sciences (Shanghai, China). NHA and primary GBM#P3 cells were kindly provided by Professor Rolf Bjerkvig (University of Bergen; Bergen, Norway). P3 cells were cultured in Dulbecco’s modified Eagles’ medium (DMEM)/F-12 medium (Thermo Fisher Scientific; Waltham, MA, USA) supplemented with 2% B27 Neuro Mix (Thermo Fisher Scientific), 20 ng/mL epidermal growth factor (EGF; Thermo Fisher Scientific), and 10 ng/mL basic fibroblast growth factor (bFGF; PeproTech; Rocky Hill, NJ, USA). All other cells were cultured in DMEM (Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific). Cells were maintained at 37 °C in a humidified chamber containing 5% CO₂.

**Lentiviral transductions**

U87MG, A172, or P3 cells were infected with lentivirus containing two different shRNAs targeting USP39 (sh-USP39-1, sh-USP39-2; OBiO Technology, Shanghai, China). After 48 h, cells were cultured in DMEM or DMEM/F-12 containing puromycin (2 μg/mL; Thermo Fisher Scientific) for an additional 2 weeks to select for cells containing the constructs. For ectopic expression of USP39 or TAZ, U87MG- and P3-sh-USP39-1 cells were infected with lentiviral constructs expressing full-length USP39 or TAZ (OBiO Technology). The sequences of the shRNAs and siRNAs used are the following: sh-negative control, 5′-UU CUCGAGAGUUCAGCUUTT-3′; sh-USP39-1, 5′-GCAU AUGAUUGUACCACUUTT-3′; sh-USP39-2, 5′-CCUUCGA CUCUAUCAUATT-3′; si-negative control, 5′-UUC CUGAAGUGUCACGUTT-3′; si-YAP, 5′-GCTCATGAT GGAGAAATTTA-3′; si-TAZ, 5′-GCTCATGAGTAT GCCCAAT-3′.

**Nuclear fractionation**

Nuclear and cytoplasmic fractions from different cell populations were isolated using Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific), according to the manufacturer’s instructions. GAPDH and Histone H3 were used for normalization.

**Immunohistochemistry**

Glioma samples were obtained from 46 patients (WHO II–IV) who had undergone surgeries performed at the Department of Neurosurgery at the Qilu Hospital. Non-neoplastic brain tissue samples were collected from six patients who underwent partial resection due to trauma or other conditions unrelated to cancer. Tissues were fixed with 4% formalin, embedded in paraffin, and sectioned (4 μm). IHC assays were performed using the SPlink Detection Kit and DAB (ZSGB-BIO; Beijing, China) according to the manufacturer’s instructions. The following primary antibodies were used: USP39 (#ab131332, 1:200, Abcam, Cambridge, MA, USA), TAZ (#ab84927, 1:200, Abcam), and Ki67 (#ab92742, 1:800, Abcam). USP39 staining was scored as follows: 0, no staining; 1, weak staining in <50% cells; 2, weak staining in ≥50% cells; 3, strong staining in <50% cells; and 4, strong staining in ≥50% cells.

**Immunofluorescence**

Cells were cultured in 24-well plates, fixed with 4% paraformaldehyde, permeabilized with 0.4% Triton X-100,
blocked with 5% bovine serum albumin, and incubated with primary antibody against TAZ (#8418, 1:200, Cell Signaling Technology, Beverly, MA, USA) at 4 °C overnight. Primary antibody was detected with an Alexa Fluor 594 conjugated goat anti-rabbit IgG antibody (#ab150080, 1:800; Abcam), and cell nuclei were stained with DAPI (Sigma-Aldrich; St. Louis, MO, USA). Images were obtained under fluorescence microscopy (Leica; Wetzlar, Germany).

**Western blotting analysis**

Cells and tissues were lysed in RIPA Lysis and Extraction Buffer (Thermo Fisher Scientific) containing a protease inhibitor cocktail (Sigma-Aldrich). Protein lysates (20 μg) were run on SDS-PAGE and transferred onto polyvinylidene difluoride membranes. Membranes were blocked in 5% skim milk, and incubated overnight with primary antibodies at 4 °C followed by incubation with secondary antibodies (ZSGB-BIO). Proteins on membranes were visualized using the Chemiluminescent Reagents Kit (Bio-Rad; Hercules, CA, USA) and quantified using Image Lab 3.0 software (Bio-Rad). The following primary antibodies were used for western blotting: USP39 (#ab131332, Abcam), Histone H3(#ab176842, Abcam), Ki67 (#ab92742, Abcam), GAPDH (#sc-25778, Santa Cruz Biotechnology; Dallas, TX, USA), LATS1 (#3477, Cell Signaling Technology), LATS2(#5888, Cell Signaling Technology), YAP (#14074, Cell Signaling Technology), and TAZ (#8418, Cell Signaling Technology).

**Cell invasion and migration assay**

Cells (2 × 10⁴/well) were seeded into the upper chamber of transwell permable supports (pore size: 8 μm; Corning Costar; Tewksbury, MA, USA), and medium containing 30% FBS (600 μL) was added into the lower chamber. For invasion assays, the upper chamber was coated with Matrigel (BD Biosciences; Bedford, MA, USA). Chambers were incubated at 37 °C for 24–36 h, and cells were fixed with 4% paraformaldehyde and stained with crystal violet (Solarbio; Beijing, China). Images were obtained from five random fields (×100) in each well. All experiments were performed in triplicate.

**Cell viability assay**

Cells (5 × 10³/well) were seeded into 96-well plates and incubated overnight. CCK8 solution (Dojindo; Kumamoto, Japan) was added to evaluate cell viability every 24 h according to the manufacturer’s instructions. Samples were measured at 450 nm in a microplate reader (PerkinElmer; San Jose, CA, USA).

**EdU assay**

Cells (2 × 10⁷/well) were seeded into 24-well plates and incubated overnight. Proliferation was evaluated using the EdU Kit (Rib-bio; Guangzhou, China) according to the manufacturer’s instructions. Images were obtained from three random fields (×200) under fluorescence microscopy (Leica).

**Colony forming assay**

U87MG and A172 cells (1 × 10³/well) were seeded into 6-well plates, and P3 cells were seeded into 6-well plates coated with poly-L-lysine (Solarbio). After 2 weeks, cells were fixed with 4% paraformaldehyde and stained with crystal violet (Solarbio). The total number of colonies was counted per well. All experiments were performed in triplicate.

**Reverse transcription PCR**

Cell and tissue RNA isolation were carried out using TRIzol Reagent (Takara; Tokyo, Japan) according to manufacturer’s instructions. Isolated total RNA was quantified and used to generate cDNA using a reverse transcription kit (Toyobo; Osaka, Japan). mRNA levels were quantified by real-time PCR. GAPDH served as an internal control. The following primers were used:

**GAPDH**
- forward, 5′-GCACCGTCAAGGCTGAGAAC-3′
- reverse, 5′-TGACCTCATTGGCCACACATGT-3′

**USP39**
- forward, 5′-TTGCTGTCCCATGATGAAGC-3′
- reverse, 5′-TGAGTAGTGGACGGC-3′

**BIRC5**
- forward, 5′-TGCAGAACCCCCATAGGAAACA-3′
- reverse, 5′-CGC ACTTTCCTCGAGTTTCC-3′

**E2F1**
- forward, 5′-GCCAT CCAGGAAAAGGTGTGA-3′
- reverse, 5′-GGTAGTGAGCAGC-3′

**MYC**
- forward, 5′-GGTAGTGAGGAACCAGAGCC-3′
- reverse, 5′-TTCTCCTCCCGTGGGC-3′

**TAZ**
- forward, 5′-GCCCAATCCGGTGTTACC-3′
- reverse, 5′-CCAGAGGATCCGAGG-3′

**Luciferase reporter assays**

Cells were seeded in 96-well plates (3 × 10³/well). After 24 h, luciferase reporter constructs containing a transcription factor responsive element upstream of firefly
luciferase were co-transfected with a Renilla luciferase construct into cells using Lipofectamine 3000 (Thermo Fisher Scientific), according to the manufacturer’s instructions. After 24 h, luciferase activity was analyzed using the Dual Luciferase Reporter Assay kit (Promega) according to the manufacturer’s protocol. Renilla activity was used to normalize luciferase reporter activity. Experiments were performed in triplicate. Plasmids used were estimated by the Kaplan–Meier survival analysis, which indicates. Data were expressed as the mean ± SEM, and statistical significance was calculated with unpaired two-tailed Student’s t-tests, unless otherwise stated. Survival curves were estimated by the Kaplan–Meier method and compared using the log-rank test. A two-sided \( \chi^2 \)-test and Fisher’s exact test were both used to determine the association between USP39 and TAZ. A two-sided \( \chi^2 \)-test was used to determine the association between USP39 expression and clinicopathological factors. GraphPad Prism version 7.00 software program (GraphPad; La Jolla, CA, USA) was used to analyze data from in vitro and in vivo experiments. Differences were considered as statistically significant when \( p < 0.05 \).

**Acknowledgements** We appreciate the assistance from other members of the lab. This work was supported by the National Natural Science Foundation of China (81701329 and 81702474), the Department of Science & Technology of Shandong Province (2016GSF01060, 2017CXGC1502, and 2018GSF118082), the Special Foundation for Taishan Scholars (ts20110814, ts201502056, and ts20161067), the Shandong Provincial Natural Science Foundation (ZR2017MH116 and ZR2017MH015), the China Postdoctoral Science Foundation (2018M642666), the Jinan Science and Technology Bureau of Shandong Province (201704096), the University of Bergen, and the K.G. Jebsen Brain Tumor Research Centre.

**Author contributions** Conception and design: JW, XYW, KKD, and JXJ. Methodology, data analysis and writing: KKD and JXJ. Acquisition of material (Reagents, animals, clinical samples): XZ, BH, AJC, DZ, and XGL. Supervision: JW and XYW.

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Ethics statement** All primary human tissue samples and subsequent experiments were approved by the Research Ethics Committee of Qilu Hospital of Shandong University (Jinan, China). Written informed consent was obtained from all patients before experiments were conducted. Animal experiments were approved and performed under the guidance of the Institutional Animal Care and Use Committee of Shandong University.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet. 2018;392:432–46.
RNA splicing factor USP39 promotes glioma progression by inducing TAZ mRNA maturation

2. Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epide-
miology and molecular pathology of glioma. Nat Clin Pract Neurol. 2006;2:494–503. quiz 491 p following 516.
3. Wen PY, Reardon DA. Neuro-oncology in 2015: progress in glioma diagnosis, classification and treatment. Nat Rev Neurol. 2016;12:69–70.
4. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet. 2003;361:323–31.
5. van Leuken RJ, Luna-Vargas MP, Sixma TK, Wolthuis RMF, Medema RH. USp39 is essential for mitotic spindle checkpoint integrity and controls mRNA-levels of aurora B. Cell Cycle. 2008;7:2710–9.
6. Sowa ME, Bennett EJ, Gygi SP, Harper JW. Defining the human deubiquitinating enzyme interaction landscape. Cell. 2009;138:389–403.
7. Makarova OV, Makarov EM, Luhrmann R. The 65 and 110 kDa SR-related proteins of the U4/U6.U5 tri-snRNP are essential for the assembly of mature spliceosomes. EMBO J. 2001;20:2553–63.
8. Lygerou Z, Christophides G, Seraphin B. A novel genetic screen for snRNP assembly factors in yeast identifies a conserved protein, Sad1p, also required for pre-mRNA splicing. Mol Cell Biol. 1999;19:2008–20.
9. Rios Y, Melmed S, Lin S, Liu NA. Zebra fish usp39 mutation leads to rbl mRNA splicing defect and pituitary lineage expansion. PLoS Genet. 2011;7:e1001271.
10. Huang Y, Pan XW, Li L, Chen L, Liu X, Lu JL, et al. Overexpression of USP39 predicts poor prognosis and promotes tumorigenesis of prostate cancer via promoting EGFR mRNA maturation and transcription elongation. Oncotarget. 2016;7:22016–30.
11. Li KY, Zhang J, Jiang LC, Zhang B, Xia CP, Xu K, et al. Knockdown of USP39 by lentivirus-mediated RNA interference suppresses the growth of oral squamous cell carcinoma. Cancer Biomark. 2016;16:137–44.
12. Wang X, Yu Q, Huang L, Yu P. Lentivirus-mediated inhibition of USP39 suppresses the growth of gastric cancer cells via PARP activation. Mol Med Rep. 2016;14:301–6.
13. Zhao Y, Zhang B, Lei Y, Sun J, Zhang Y, Yang S, et al. Knockdown of USP39 induces cell cycle arrest and apoptosis in melanoma. Tumour Biol. 2016;37:13167–76.
14. Gan Z, Han K, Lin S, Hu H, Shen Z, Min D. Knockdown of ubiquitin-specific peptidase 39 inhibited the growth of osteosarcoma cells and induced apoptosis in vitro. Biof Res. 2017;50:15.
15. Wang H, Ji X, Liu X, Yao R, Chi J, Liu S, et al. Lentivirus-mediated inhibition of USP39 suppresses the growth of breast cancer cells in vitro. Oncol Rep. 2013;30:2871–7.
16. Yuan X, Sun X, Shi X, Jiang C, Yu D, Zhang W, et al. USP39 promotes the growth of human hepatocellular carcinoma in vitro and in vivo. Oncol Rep. 2015;34:823–32.
17. An Y, Yang S, Guo K, Ma B, Wang Y. Reduced USP39 expression inhibits malignant proliferation of medullary thyroid carcinoma in vitro. World J Surg Oncol. 2015;13:255.
18. Lin ZF, Xiong LW, Lin Q. Ubiquitin-specific protease 39 is overexpressed in human lung cancer and promotes tumor cell proliferation in vitro. Mol Cell Biochem. 2016;422:97–107.
19. Cai J, Liu T, Huang P, Yan W, Guo C, Xiong L, et al. USP39, a direct target of microRNA-133a, promotes progression of pancreatic cancer via the AKT pathway. Biochem Biophys Res Commun. 2016;478:184–90.
20. Xing ZY, Sun FB, He W, Wang ZW, Song QX, Zhang FJ. Downregulation of ubiquitin-specific peptidase 39 suppresses the proliferation and induces the apoptosis of human colorectal cancer cells. Oncol Lett. 2018;15:5443–50.
21. Xu Y, Zhu MR, Zhang JY, Si GM, Lv JJ. Knockdown of ubiquitin-specific peptidase 39 inhibits the malignant progression of human renal cell carcinoma. Mol Med Rep. 2018;17:4729–35.
22. Pan DJ. The hippo signaling pathway in development and cancer. Dev Cell. 2010;19:491–505.
23. Harvey KF, Pfleger CM, Hariharan IK. The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell. 2003;114:457–67.
24. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, et al. The hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 2011;147:759–72.
25. Piccolo S, Dupont S, Cordenonsi M. The biology of Yap/Taz: hippo signaling and beyond. Physiol Rev. 2014;94:1287–312.
26. Ehmer U, Sage J. Control of proliferation and cancer growth by the hippo signaling pathway. Mol Cancer Res. 2016;14:127–40.
27. Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA, Donowitz M, et al. TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J. 2000;19:6778–91.
28. Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, et al. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol. 2008;28:2426–36.
29. Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao SM, et al. TAZ transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Biol Chem. 2009;284:13355–62.
30. Nallet-Staub F, Marsaud V, Li L, Gilbert C, Dodier S, Bataille V, et al. Pro-invasive activity of the hippo pathway effectors YAP and TAZ in cutaneous melanoma. J Invest Dermatol. 2014;134:123–32.
31. Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu P, et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. P Natl Acad Sci USA. 2010;107:1437–42.
32. Wang L, Shi SJ, Guo ZY, Zhang X, Han SX, Yang AG, et al. Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. Plos One. 2013;8:e56539.
33. Li WJ, Dong SC, Wei W, Zhang GX, Zhang AL, Pu PY, et al. The role of transcriptional coactivator TAZ in gliomas. Oncotarget. 2016;7:82686–99.
34. Bhat KP, Salazar KL, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F, et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev. 2011;25:2594–609.
35. Fraile JM, Manchado E, Lujambio A, Quesada V, Campos-Islas D, Webb TR, et al. USP39 deubiquitination is essential for KRAs oncogene-driven cancer. J Biol Chem. 2017;292:4164–75.
36. Choi W, Kim J, Park J, Lee DH, Hwang D, Kim JH, et al. YAP/TAZ initiates gastric tumorigenesis via upregulation of MYC. Cancer Res. 2018;78:3306–20.
37. Ji J, Xu R, Zhang X, Han M, Xu Y, Wei Y, et al. Actin like-6A promotes glioma progression through stabilization of transcriptional regulators YAP/TAZ. Cell Death Dis. 2018;9:517.
38. Zhang H, Geng D, Gao J, Qi Y, Shi Y, Wang Y, et al. Expression and significance of hippo/YAP signaling in glioma progression. Tumour Biol. 2016;37:15656–76.
39. Diamantopoulos Z, White G, Faddullah MZH, Dreger M, Pickering K, Maltas J, et al. TIA1 antagonizes TAZ/YAP both in the destruction complex in the cytoplasm and in the nucleus to inhibit invasion of intestinal epithelial cells. Cancer Cell. 2017;31:626–634 e626.
40. Deel MD, Slemonns KK, Hinson AR, Genadry KC, Burgess BA, Crose LES, et al. The transcriptional coactivator TAZ is a potent mediator of alveolar rhodobromocarcinoma tumorigenesis. Clin Cancer Res. 2018;24:2616–30.
41. Chan SW, Lim CJ, Loo LS, Chong YF, Huang C, Hong W, et al. TEADs mediate nuclear retention of TAZ to promote oncogenic transformation. J Biol Chem. 2009;284:13437–58.
42. Miranda MZ, Bialik JF, Speight P, Dan Q, Yeung T, Szaszi K, et al. TGF-beta1 regulates the expression and transcriptional activity of TAZ protein via a Smad3-independent, myocardin-related transcription factor-mediated mechanism. J Biol Chem. 2017;292:14902–20.

43. Chen J, Crutchley J, Zhang D, Owzar K, Kastan MB. Identification of a DNA damage-induced alternative splicing pathway that regulates p53 and cellular senescence markers. Cancer Discov. 2017;7:766–81.

44. Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S, et al. YAP/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. Cell. 2014;158:157–70.

45. Azzolin L, Zanconato F, Bresolin S, Forcato M, Basso G, Bicciato S, et al. Role of TAZ as mediator of Wnt signaling. Cell. 2012;151:1443–56.

46. Yuan X, Sun X, Shi X, Wang H, Wu G, Jiang C, et al. USP39 promotes colorectal cancer growth and metastasis through the Wnt/beta-catenin pathway. Oncol Rep. 2017;37:2398–404.